### Abstract Titles

All approved abstracts EXCLUSIVE Case Reports and Trials in Progress will be published in the online supplement issue of NEUROENDOCRINOLOGY subsequent to the conference.

All approved abstracts INCLUSIVE Case Reports and Trials in Progress will be presented in the poster exhibition in the exhibition hall and in MY ENETS after the conference.

(Media Library, www.enets.org/my_enets)

### A. BASIC SCIENCE - SIGNALING PATHWAYS, RECEPTORS, BIOMARKERS

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>A01</td>
<td>Long Noncoding RNA HNF1A-AS1 Targeting Oncostatin M Expression Inhibits Epithelial-Mesenchymal Transition via TGFβ Signaling in Gastroenteropancreatic Neuroendocrine Neoplasms</td>
<td>Bai JA et al.</td>
</tr>
<tr>
<td>B01</td>
<td>A Spatial Proteomics Approach Identifies Novel Immuno-Oncology Markers for Merkel Cell Carcinoma</td>
<td>Blenkiron C et al.</td>
</tr>
<tr>
<td>A02</td>
<td>Dose and Time-Dependent Effect of Chloroquine on Autophagosome Generation in a Typical Bronchial Carcinoid Cell Line</td>
<td>Borges de Souza P et al.</td>
</tr>
<tr>
<td>B02</td>
<td>EGFR and IGF1R Impair Sunitinib Activity and May Represent Novel Targets for Broncho-Pulmonary Neuroendocrine Neoplasm Treatment</td>
<td>Bresciani G et al.</td>
</tr>
<tr>
<td>A03</td>
<td>Immunoprofiling in Neuroendocrine Neoplasms: Implications for Immunotherapy</td>
<td>Busse A et al.</td>
</tr>
<tr>
<td>A04</td>
<td>Expression Signature of GEP-NETs in Correlation to Clinical Outcome at ENETS CoE in Switzerland</td>
<td>Duschek S et al.</td>
</tr>
<tr>
<td>A05</td>
<td>Efficacy of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells</td>
<td>Herrera-Martínez AD et al.</td>
</tr>
<tr>
<td>A06</td>
<td>Combination of 5-Fluorouracil (5-FU) with DNMTs or HDACs as Epigenetic Modifiers Has Synergistic Effects on Radiosensitization and Somatostatin Receptor sstr 2 Expression in Human Neuroendocrine Tumor Cells</td>
<td>Jin XF et al.</td>
</tr>
<tr>
<td>A07</td>
<td>The Porcupine (PORCN) Inhibitor WNT974 Exerts Multiple Anticancer Activities in Neuroendocrine Tumor Cell Lines in Vitro</td>
<td>Jin XF et al.</td>
</tr>
<tr>
<td>A08</td>
<td>Development of Diagnostic Biomarkers of Lung Neuroendocrine Tumors by the Detection of Cancer-Derived Protein Fragments in the Urine Using Original Mass Spectrometric Methods</td>
<td>Nakazato M et al.</td>
</tr>
<tr>
<td>A09</td>
<td>Evaluation of Gene Expression Changes Associated with Response to Somatostatin Analogues (SSAs) in Gastrointestinal (GI) Neuroendocrine Tumors (NETs)</td>
<td>Teufel A et al.</td>
</tr>
<tr>
<td>A10</td>
<td>Identification of Novel IgG Type Tumor Marker in Non-Functional Pancreatic Neuroendocrine Tumors by SEREX Method</td>
<td>Tsuchikawa T et al.</td>
</tr>
<tr>
<td>B03</td>
<td>Influence of Tumor Microenvironment in Response Modulation to Treatment in Human Broncho-Pulmonary Neuroendocrine Neoplasm</td>
<td>Brusciani G et al.</td>
</tr>
<tr>
<td>B04</td>
<td>Using Adult Stem Cell-Derived Organoids to Model Neuroendocrine Neoplasms</td>
<td>Dayton T et al.</td>
</tr>
<tr>
<td>A12</td>
<td>Establishment of Patient-Derived Tumor Organoid (PDTO) Derived from Pancreatic Neuroendocrine Tumor</td>
<td>Ichikawa Y et al.</td>
</tr>
<tr>
<td>B05</td>
<td>Combined Autophagy and mTOR Inhibition Reduces Cells Proliferation and Induces Apoptosis in a Lung Carcinoid In-Vitro Model</td>
<td>Knigin A et al.</td>
</tr>
<tr>
<td>A13</td>
<td>Evaluating Novel Inhibition of FOXM1 Signaling Pathways as Targets in Gastroenteropancreatic Neuroendocrine Cells</td>
<td>Sedding DJH et al.</td>
</tr>
<tr>
<td>B07</td>
<td>Downregulation of TAK1 Inhibit Migration and Invasion in Neuroendocrine Tumor Cells</td>
<td>Yang X et al.</td>
</tr>
</tbody>
</table>

### B. BASIC SCIENCE - IN VITRO MODELS, TUMOR GROWTH, CTCS

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>B01</td>
<td>Cancer Associated Fibroblasts Stimulate Proliferation and Induce Resistance to Everolimus in Neuroendocrine Tumor Cells</td>
<td>Amin T et al.</td>
</tr>
<tr>
<td>B02</td>
<td>Available 3D Cultures Methods: Study on a Pancreatic Neuroendocrine Neoplasm Cell Line</td>
<td>Bresciani G et al.</td>
</tr>
<tr>
<td>B03</td>
<td>Influence of Tumor Microenvironment in Response Modulation to Treatment in Human Broncho-Pulmonary Neuroendocrine Neoplasm</td>
<td>Brusciani G et al.</td>
</tr>
<tr>
<td>PW</td>
<td>Using Adult Stem Cell-Derived Organoids to Model Neuroendocrine Neoplasms</td>
<td>Dayton T et al.</td>
</tr>
<tr>
<td>B05</td>
<td>Establishment of Patient-Derived Tumor Organoid (PDTO) Derived from Pancreatic Neuroendocrine Tumor</td>
<td>Ichikawa Y et al.</td>
</tr>
<tr>
<td>B06</td>
<td>Combined Autophagy and mTOR Inhibition Reduces Cells Proliferation and Induces Apoptosis in a Lung Carcinoid In-Vitro Model</td>
<td>Knigin A et al.</td>
</tr>
<tr>
<td>B07</td>
<td>Evaluating Novel Inhibition of FOXM1 Signaling Pathways as Targets in Gastroenteropancreatic Neuroendocrine Cells</td>
<td>Sedding DJH et al.</td>
</tr>
<tr>
<td>B08</td>
<td>Downregulation of TAK1 Inhibit Migration and Invasion in Neuroendocrine Tumor Cells</td>
<td>Yang X et al.</td>
</tr>
</tbody>
</table>

*The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.
C. BASIC SCIENCE - GENETICS, EPIGENETICS, MIRNAS, OMICS

**OA (C01)** Alcala N et al. Integrative and Comparative Genomic Analyses Identify Clinically Relevant Groups of Pulmonary Carcinoids and Unveil the Existence of Supra-Carcinoids

**PW (C02)** Berner A et al. PUnNETS (Prediction of Unknown Neuroendocrine Tumour Site) – A DNA Methylation-Based Classifier

**PW (C03)** Blazevic A et al. Proteomic Analysis of Small Intestinal Neuroendocrine Tumours and Associated Mesenteric Fibrosis Reveals Primarily Differences in Mesenteric Stroma

**OA (C04)** Cros J et al. Genomic Landscape of Pulmonary Carcinoids with High Grade Progression

**PW (C05)** Dou D et al. MicroRNA-202-3p As a Potential Diagnostic Biomarker for Type 1 Gastric Neuroendocrine Tumor

**PW (C06)** Jian-An B et al. Octreotide-Conjugated Core Cross-Linked Micelles with pH/Redox Responsivity Loaded with Etoposide for Neuroendocrine Neoplasms Therapy and Bioimaging with Photoquenching Resistance

**OA (C07)** La Salvia A et al. Extra-Pulmonary Neuroendocrine Carcinomas Display Distinct Transcriptional Profiles According to the Site of Origin

**PW (C08)** Mandriani B et al. The Genomic Landscape of Small Nonfunctioning pNETs

**OA (C09)** Melchior LC et al. Next Generation Sequencing of 294 Neuroendocrine G3 and Mixed Neuroendocrine and Non-Neuroendocrine Neoplasms Identifies Molecular Profile Linked to the Site of the Primary and Tumor Composition

**PW (C10)** Pedraza-Arévalo S et al. Drastic Dysregulation in Splicing Machinery and Its Association with Aggressiveness Features in Pancreatic Neuroendocrine Tumors

**OA (C11)** Robb T et al. Understanding Tumour Evolution of a Highly Disseminated Lung NET Through Multi-Player Augmented Reality Visualisation

**PA (C12)** Sadanandam A et al. Immune Characteristics of Pancreatic Neuroendocrine Tumors According to Grade and Molecular Subtypes

**PW (C13)** Simbolo M et al. Next Generation Sequencing and Transcriptome Analysis Identify Common Genomic Signatures for Atypical Carcinoids and Large Cell Neuro-Endocrine Carcinomas of the Lung

**OA (C14)** Sposito T et al. The PanNET-Related Histone H3.3 Chaperone Daxx Regulates Lineage Specification and Tissue Homeostasis in the Pancreas

**PW (C15)** Tirosh A et al. Distinct Genome-Wide Methylation Patterns in Sporadic and Hereditary Nonfunctioning Pancreatic Neuroendocrine Tumors

**PW (C16)** Vicentini C et al. Distinct Transcriptional Signatures of ATRX and DAXX Mutated PanNETs

**C17** Wang Z et al. Uncovering the Heterogeneous Genetic Variations in Two Insulin-Expressing Tumors in a Patient with MEN1

D. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - REGISTRIES, NATIONWIDE AND REGIONAL SURVEYS

**D01** Altieri B et al. Natural History and Prognostic Factors of Survival in Localized and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Resection: A Multicenter Study Among Italian and French ENETS Centers

**D02** Bai JA et al. Clinical Features of Rectal Neuroendocrine Neoplasms and Risk Factors for Metastasis

**OA (D03)** Blazevic A et al. Influence of Gender on the Evolution of Mesenteric Metastases in Small Intestinal Neuroendocrine Tumours

**D04** Bottiglieri F et al. Pitfalls in Diagnosis of Insulinomas: Multidisciplinary and Experienced Approach

**D05** Boumansour NFZ et al. Epidemiological Profile of Neuroendocrine Tumors in Western Algeria 2017-2018

**D06** Brabo EP et al. Clinical Presentation and Diagnostic Delay in a Series of MEN1 Patients in Brazil

**D07** Brabo EP et al. Survival Outcomes of Extra Pulmonary Neuroendocrine Carcinomas in a Single Center in Brazil

**D08** Buikhuisen W et al. Association between Pulmonary Carcinoids (PC) and Other Types of Cancer

**D09** Chraiet N et al. Neuroendocrine Tumors: A 20-Years’ Experience of the Salah Azaiez National Cancer Institute in Tunisia

**D10** Clement D et al. NET Patients’ Report Significant Time to Diagnosis from Onset of Symptoms

**D11** Cosaro E et al. Clinico-Pathological Features, Treatment Modalities and Prognosis of Patients with Malignant Insulinoma: Preliminary Data From a Multicentre Study
Abstract

(D12) Cuypers A et al. Neuroendocrine Neoplasms Grade 3: Prospective Overall Survival Data and Survival after Platinum-Etoposide Chemotherapy within an ENETS Center of Excellence

(D13) Darden C et al. Satisfaction Survey of Administration Modes for Long-Acting (LA) Somatostatin Analog (SSA) Therapy in Patients (pts) with Neuroendocrine Tumors (NETs): Results of Cognitive Interviews with Patients and Nurses

(D14) De Cicco F et al. Neuroendocrine Tumors in Elderly: Clinical Presentation, Prognosis and Therapy

(D15) De Groot E et al. Overview of Neuroendocrine Patient Demographics and Outcomes in the Leicestershire Region

(D16) Devlin L et al. Neuroendocrine Tumour (NET) Patients Experiences of Support in the Community Setting Across the Cancer Treatment Trajectory

(D17) Exarchou K et al. Endoscopic Surveillance Is a Viable Alternative Management Strategy for Patients with Localised Small Non-Functional Low Grade Duodenal Neuroendocrine Tumours (dNETs)

(D18) Fan JH et al. Clinical Epidemiology Study of Gastric Neuroendocrine Neoplasms in China: A National Multicenter 10-Year Retrospective Study

(D19) Fatima A et al. Evaluating the Impact of Treatment, Disease Burden and Disease Status on Quality of Life among Patients Diagnosed with Neuroendocrine Tumors

(D20) Furtado O'Mahony L et al. Combination of 68Ga-DOTATATE and 18F-FDG PET/CT in Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEPNET) - Clinical and Prognostic Implications

(D21) Furtado O'Mahony L et al. Utility of 68Ga DOTATATE PET in Challenging Neuroendocrine Neoplasms’ Scenarios

(D22) Gao H et al. The Distinct Clinicopathological and Prognostic Features of Insulinoma with Synchronous Distant Metastasis

(D23) Glaser JM et al. Incidence of Secondary Malignoma in Patients with Gastro-Enteropancreatic Neuroendocrine Neoplasia

(D24) Goudet P et al. Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1. A GTE and AFCE Cohort Study (Groupe d’étude des Tumeurs Endocrines et Association Francophone de Chirurgie Endocrinienne)

(D25) Hadoux J et al. Characteristics and Outcome of Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC) Occurring in Previously Irradiated Areas

(D26) Hayes AR et al. Metastases to the Breast in Patients with Metastatic Neuroendocrine Tumours (NET) Clinicopathological and Imaging Characteristics

(D27) Heidsma C et al. The PANDORA Study, A Prospective Cohort of Conservatively Treated, Non-Functional Pancreatic Neuroendocrine Tumors < 2 cm

PW (D28) Jimenez-Fonseca P et al. Nomogram to Predict Progression-free Survival in Patients with Well-differentiated, Stage IV Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues: Data of TRASGU-GETNE Study

PW (D29) Kamieniarz L et al. Diagnostic Features and Management Options for Duodenal (Non-Ampullary) Neuroendocrine Neoplasms: Results from a Multi-Centre Series

(D30) Kamieniarz L et al. Orbital Metastases from Neuroendocrine Tumours: Epidemiology and Clinical Implications

(D31) Khalil M et al. Is the Cystic Character of a Pancreatic Neuroendocrine Tumor a good Prognosis Factor?

(D32) Khan M et al. Improving Patient Outcomes: Development of a Patient-Centred Service for Neuroendocrine Tumours in Wales through Population-Based National Commissioning

(D33) Koca E et al. Establishment of a NET Data Base in a German Tertiary Referral Center Preliminary Results

PW (D34) Kolarova T et al. Unmet Needs in Global Neuroendocrine Tumour (NET) Care: Similarities and Differences in the Perspectives of Patients, Patient Advocates and NET Health Professionals

(D35) Kooyker A et al. Change in Incidence, Characteristics and Management of Colorectal Neuroendocrine Tumors in the Netherlands in the Last Decade

OA (D36) Kuiper T et al. Endoscopically Removed Colorectal NETs; A Nationwide Cohort Study

(D37) Leigh C et al. Myocardial Metastases in Neuroendocrine Tumours: Epidemiology and Clinical Implications

(D38) Lider Burciulescu SM et al. The Response in Patients with Pheochromocytoma to the Antihypertensive Drugs Correlated with the Values of the Catecholamine and with Mutation

(D39) Magi L et al. Presentation and Multidisciplinary Management of Neuroendocrine Neoplasia

(D40) Mandal N et al. Psycho-Social Problem: My Time with Cancer

*The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.
(D41) **Mazza M et al.** Management of Small Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Tumors: From Guidelines to Real Life

(D42) **Michael M et al.** Incidence, Prevalence and Survival Trends for NETs/NECS in Victoria, Australia, from 1982-2016: Based on Site, Grade and Region

(D43) **Modica R et al.** Duodeno Pancreatic Neuroendocrine Tumors (DPNET) in Multiple Endocrine Neoplasia Type 1 (MEN1): An Italian Restrospective, Observational, Multicenter Study

(D44) **Murgioni S et al.** Neuroendocrine Neoplasm in Real World Practice: A Large and Modern Single Institution Experience

(D45) **Parker K et al.** The NETwork! Registry Analysis Supports the WHO 2017 Classification in the First NET Specific Survival Analysis for a Complete Population

(D46) **Pellé E et al.** An Immunohistochemical Score as Predictor of the Bone Metastasis Risk in Patients with NETs

(D47) **Peralta Ferreira M et al.** Gastric Neuroendocrine Tumors Workup – Classification and Treatment Challenges

(D48) **Pranoy S et al.** Evaluation of Nutritional Deficiencies in a New Gastroenterology-led South Wales Neuroendocrine Tumour (NET) Service

(D49) **Rinzivillo M et al.** Prognostic Impact of Tumor Burden In Stage IV Neuroendocrine Neoplasia: A Comparison Between Pancreatic and Gastrointestinal Localizations

(D50) **Rinzivillo M et al.** Tumor Type and Size Are Prognostic Factors in Gastric Neuroendocrine Neoplasia: A Multicentre Retrospective Study

(D51) **Rossi RE et al.** Second Primary Malignancies in Patients with Gastro-Entero-Pancreatic Neuroendocrine Neoplasia (GEP-NEN)

(D52) **Santos AP et al.** Obesity and Metabolic Syndrome Don’t Seem to Influence Progression Free Survival in Well Differentiated GEP-NETs

(D53) **Siebenhüner A et al.** Treatment Landscape of GEP-NETs in Correlation to Clinical Outcome at ENETS CoE in Switzerland

(D54) **Song L et al.** A Retrospective Analysis of 117 Patients with Esophageal Neuroendocrine Tumors

(D55) **Song L et al.** Clinical Analysis on 547 Patients with Neuroendocrine Tumors in a Chinese Population: A Single-Center Study

(D56) **Tanno L et al.** What Is the Burden of Treatment in Patients with Small Bowel Neuroendocrine Tumour? A UK Regional Single Centre Experience

(D57) **Tarquini M et al.** Evaluation of NEP-SCORE Applicability in a Series of Patients with IV Stage NEN

(D58) **Uema D et al.** High Tumor Burden and Treatment in the Public Setting Are Associated with Carcinoid Heart Disease and Decreased Overall Survival: A Multicenter and Multinational Study

(D59) **Van Beek DJ et al.** Prognostic Factors and Survival in MEN1 Patients with Gastrinomas: Results from the DutchMEN Study Group (DMSG)

(D60) **Whyand T et al.** The Essential Role of Functional Nutrition Assessment in NET Clinics

(D61) **Wyld D et al.** Incidence and Survival of Small Intestinal Neuroendocrine Tumours in Queensland, Australia, 2001-2015

(D62) **Yalcin S et al.** Gastroenteropancreatic Neuroendocrine Tumors (GEPNET) Registry 2009-2018: Results of Collaborative Effort Including over 1000 Patients (Pts) with GEPNET from 15 Countries

(D63) **Zhang S et al.** Clinicopathological Characteristics and Prognostic Predictors of Gastroenteropancreatic Neuroendocrine Neoplasms: A Nation-Wide 10-Year Retrospective Study in China

---

**E. PATHOLOGY - GRADING, STAGING**

(E01) **Chiranth DJ et al.** Incidence and Clinicopathological Features of Colorectal Neuroendocrine Carcinomas and Mixed Neuroendocrine-Nonneuroendocrine Neoplasms

(E02) **De Barros E Silva MJ et al.** Ki-67 Index as a Useful Tool to Distinguish Different Evolution and Clinicopathological Features in Normogastrinemic Gastric Neuroendocrine Tumors

(E03) **Emelianova G et al.** Value of Re-Biopsy of Liver Metastases of Patients with Neuroendocrine Tumors in Disease Progression

(E04) **Kasajima A et al.** Prognostic Impact of Ki-67 Index and WHO2017 Classification in Bronchopulmonary Neuroendocrine Neoplasm

(E05) **Rubino M et al.** Lung Carcinoid with High Proliferation Index (G3 lung NET): Frequency, Prognosis and Response to Systemic Therapy
| (E06) | Waldum H et al. Hepatic Neuroendocrine (NE) Micrometastases Outside Macrometastases Are Found in All Patients with Ileal Primary Tumour at the Time of Liver Resection |
| (E07) | Zhang P et al. Clinicopathological Features and Metastatic Patterns of Patients with Gastroenteropancreatic Mixed Adenoneuroendocrine Carcinoma |

**F. BIOMARKERS**

| (F01) | Abudureheiyimu N et al. Correlation Analysis between Neuroendocrine Neoplasm and Immunophenotype Expression in Different Sites |
| (F02) | Andreasi V et al. Association between Preoperative Vasostatin-1 and Pathological Features of Aggressiveness in Localized Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET) |
| (F03) | B XL et al. Comprehensive Genomic Profiling of Chinese Patients with Neuroendocrine Neoplasm |
| (F04) | Bodei L et al. Circulating Neuroendocrine Tumor Gene Expression for Monitoring Peptide Receptor Radionuclide (PRRT) Efficacy |

**PW (F05)** | Botling J et al. Longitudinal Increase in Ki-67 and High-Grade Transformation in Pancreatic Neuroendocrine Tumors (PNETs) |

| (F06) | Chan D et al. Computed Tomography (CT) - Defined Sarcopenia Is Prevalent in Patients with Neuroendocrine Neoplasms (NENs) |
| (F07) | Ewang-Emukowhate M et al. Assessment of Fat-Soluble Vitamins and Trace Elements in Patients with Neuroendocrine Tumours (NET) on Somatostatin Analogues (SSA) |
| (F08) | Fatima A et al. Finding the Link between Transforming Growth Factor β-1 (TGFβ-1) and Neuroendocrine Tumor Cells. A Role in Carcinogenesis |
| (F09) | Fatima A et al. The Need of NET Diagnostic Biomarkers for Early Detection and Targeted Management. Should Biomarkers Reflect Disease Progression? |
| (F10) | Grønbæk H et al. Relationship between Biomarkers and Number of Liver Metastases at the Time of Diagnosis of Small Intestinal Neuroendocrine Tumors |
| (F11) | Gurevich L et al. Prognostic Value of Decreased Membrane Expression NDRG1 in Neuroendocrine Tumors of Different Localization and Degree of Malignancy |
| (F12) | Halfdanarson T et al. Impact of Continuous and Categorical Covariates on the Determination of 5-Hydroxyindoleacetic Acid in Urine |
| (F13) | Hermans B et al. DLL3 in Large Cell Neuroendocrine Carcinoma (LCNEC) Associated with Molecular Subtypes |
| (F14) | Laskaratos F et al. Circulating Transcript Analysis (NETest) Assessment in the Follow-up (F/U) of Resected Midgut Neuroendocrine Tumours (NETs) |
| (F15) | Laskaratos F et al. Circulating Transcripts of Profibrotic Genes in the NETest Can Identify Mesenteric Fibrosis in Midgut Neuroendocrine Tumours (NETS) |
| (F16) | Liu Z et al. A Retrospective Analysis of PD-1/PD-L1 and DNA Mismatch Repair Proteins Expression in Neuroendocrine Neoplasms |
| (F17) | Liu Z et al. A Retrospective Analysis of SSTR2 and MGMT Expression in Neuroendocrine Neoplasms |
| (F18) | Malczewska A et al. NETest Is Diagnostic for Gastric NETs and Identifies Microscopic and Macroscopic Disease |
| (F19) | Malczewska A et al. NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease |
| (F20) | Malczewska A et al. Validation of the NETest as a Diagnostic for Rectal Neuroendocrine Tumors |
| (F21) | Malczewska A et al. Validation of the NETest Liquid Biopsy as a Diagnostic for Small Intestine and Pancreatic Neuroendocrine Tumors |

**PW (F23)** | Modlin I et al. Automated Finger Prick Blood Genomic Diagnosis of Neuroendocrine Tumors |

| (F24) | Oleinikov K et al. ProGRP is an Effective Marker for Disease Monitoring in Lung Carcinoids with Non-Informative Chromogranin A: Lessons from Clinical Practice |
| (F25) | Tsolakis A et al. Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel IHC Markers |

*The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.*
G. IMAGING AND INTERVENTIONS (RADIOLOGY, ENDOSCOPY)

(G01) Fine C et al. Endoscopic Management of 345 Small Rectal Neuroendocrine Tumours: A National Study from the French Group of Endocrine Tumours (GTE)

(G02) Izaaryene J et al. Transarterial Chemoembolization of Liver Metastatic Neuroendocrine Tumors

(G03) Lamarca A et al. Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study

(G04) Lazaridis N et al. Endoscopic Submucosal Dissection (ESD) of Gastric and Rectal Neuroendocrine Tumours (NETs)

(G05) Rinzivillo M et al. Texture Analysis on Contrast-Enhanced Computed Tomography in Liver Metastases from Pancreatic and Non-Pancreatic Neuroendocrine Neoplasia

(G06) Trifanov V et al. Experience in Treatment of Hepatic Metastases of Neuroendocrine Tumors Using Transarterial Chemoembolization

H. MEDICAL TREATMENT - CHEMOTHERAPY SOMATOSTATIN ANALOGUES, INTERFERON

(H01) Bengueddach A et al. Capecitabine Temozolomide Efficacy and Tolerability in Metastatic Neuroendocrine in G2 Neuroendocrine Neoplasm

(H02) Bengueddach A et al. Primitive Mammary Neuroendocrine Tumor: About Tow Rares Cases

(H03) Brighi N et al. Biliary Stone Disease in Patients Receiving Somatostatin Analogs for Neuroendocrine Neoplasms (NEN): An Italian Multicenter Study

(H04) Brighi N et al. Non-Conventional Doses of Somatostatin Analogs in Well-Differentiated NET Patients at Disease Progression (PD) on RECIST Criteria: An Italian Multicenter Analysis

(H05) Chan D et al. Temozolomide in Grade 3 Neuroendocrine Neoplasms (G3 NENs): A Multicentre Retrospective Review

(H06) Chatzellis E et al. Efficacy and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms

(H07) De Mestier L et al. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses

(H08) De Mestier L et al. Temozolomide (TEM) vs Temozolomide-Capecitabine (CAP) in Advanced Pancreatic NET (pNET): A Multicenter Retrospective Analysis of 138 Patients Using a Propensity Score

(H09) Elvebakken H et al. A Consensus Developed Morphological Re-evaluation of 196 Cases with Metastatic High-grade Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN G3) from the Nordic NEC Registries: Consequences for Classification, Treatment Response and Survival

(H10) Girot P et al. Oxaliplatin and 5-Fluorouracil (FOLFOX) in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A National Retrospective Study from the French Group of Endocrine Tumors (GTE)

(H11) Granja Ortega M et al. Non-Functioning Neuroendocrine Tumors Treated with Somatostatin Analogs on the Frontline: Management after Progression in Clinical Practice

(H12) Mao R et al. Effectiveness of Adjuvant Chemotherapy for Patients with Poorly Differentiated Colorectal Neuroendocrine Carcinomas: A Study of the National Cancer Database

(H13) Markovich A et al. Experience of Long-Acting SSA Administration in Patients with Well-Differentiated Gastro NETs

(H14) Martin W et al. Development of a New and Improved Delivery System (DS) for Lanreotide Autogel/Depot (LAN) to Further Enhance Patient Care


(H16) Oziel-Taieb S et al. Outcome Analysis of FOLFOX Chemotherapy Treatment in Metastatic Neuroendocrine Tumors

(H17) Pavel M et al. Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study

(H18) Prasad V et al. Tumour Growth Rate (TGR) to Monitor Growth/Predict Response to Lanreotide Autogel (LAN) Use before, during and after Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs): Data from PRELUDE

(H19) Pusceddu S et al. Post-Hoc Analysis of CLARINET Phase III Study to Investigate the Influence of Diabetic Status on Progression-Free Survival (PFS) of Patients with Neuroendocrine Tumours (NETs) Treated with Lanreotide (LAN) or Placebo (PBO)
Abstract Titles

(H20) Reher D et al. Response of the Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Treated with Streptozotocin/5-FU – A Preliminary Retrospective Study

(H21) Scala S et al. IMMUNeOCT: Octreotide LAR in the Induction of Immunologic Response in Patients (pts) with Neuroendocrine Neoplasms (NENs): A Perspective Observational and Translational Study

(H22) Smiroldo V et al. Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (CAPTEM) in Patients with Metastatic Neuroendocrine Tumors (NETs). A 5-Years Single-Institution Experience

(H23) Strosberg J et al. Patient-Reported Carcinoid Syndrome Symptom Improvement after Initiating Telotristat Ethyl in the Real World

(H24) Szpak W et al. Response to Treatment and Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumours Treated with Lanreotide Autogel in South Africa

(H25) Villabona C et al. Evaluation of the Use of Resources and Costs Associated with Uncontrolled or Controlled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs) in Spain: RECOSY Study

I. MEDICAL TREATMENT - TARGETED THERAPIES

OA (I01) Apostolidis L et al. Treatment Strategies Derived from Comprehensive Genomic and Transcriptomic Analysis in Patients with Advanced-Stage Neuroendocrine Neoplasms: Results from the MASTER Trial of the German Cancer Consortium

(I02) Athar A et al. Palliative Chemotherapy a Treatment Option for Large Cell Neuroendocrine Carcinoma

(I03) Capdevila J et al. Efficacy and Safety Analyses of the TALENT Trial (GETNE 1509): A Phase II Study of Lenvatinib in Patients (pts) with Advanced G1/G2 Pancreatic (panNETs) and Gastrointestinal (giNETs) Neuroendocrine Tumors

(I04) Chan D et al. Age>70 Predicts Everolimus Toxicity in Patients with NEN: A Retrospective Review

(I05) De A et al. Smart Polymeric Nanoparticles of Temozolomide for Enhancement of Brain Targeting?

(I06) Hermans B et al. Prevalence and Prognostic Value of PD-L1 Expression in Molecular Subtypes of Metastatic Large Cell Neuroendocrine Carcinoma (LCNEC)

(I07) Kuznetsova A et al. Efficiency of SUNITINIB in Treatment of PNETs Depending on Various Factors

(I08) Mauro C et al. Opportunist Infections in Patients with Neuroendocrine Tumors Treated with Everolimus: A Multicenter Study

(I09) Molina-Cerrillo J et al. TKI/mTOR Sequencing in Pancreatic Neuroendocrine Tumors (pNET): Experience in a Tertiary Referral Hospital

(I10) Morizane C et al. A Phase II Study of Everolimus in Patients with Unresectable Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy

(I11) Nunez JE et al. The Efficacy of Everolimus and Sunitinib in Patients with Sporadic or Germline Mutated Metastatic Pancreatic Neuroendocrine Tumors

J. MEDICAL TREATMENT - OTHERS, NOT SPECIFIED

(J01) Armentano DP et al. Gamma-Glutamyl Transferase (GGT) as an Early Predictor of Better Progression-Free Survival in Well-Differentiated Gastroenteropancreatic Neuro-Endocrine Tumors (GEP-NET) in Different Lines of Treatment

(J02) Dou D et al. The Role of TCM in the Treatment of Type 1 Gastric Neuroendocrine Tumor: A Clinical Observation of a Single Center in China

(J03) García-Garro S et al. Direct Impact of Clinical Research in Metastatic G1 and G2 Neuroendocrine Tumors (NETs): A Cost-Effectiveness Analysis of Patient Care Outcomes and Cost Savings in a Real-Life Scenario of a Large Public University Hospital in Spain

OA (J04) Godthelp A et al. Social Consequences of Disease-Related Symptoms in Patients with a Metastatic Small Bowel Neuroendocrine Tumor: A Qualitative Study

(J05) Hayes AR et al. Understanding Treatment Algorithms in Patients with Metastatic Pancreatic Neuroendocrine Tumours (mPNET)

(J06) Hernando J et al. „Dones en Actiu” (Active Women), A Collaborative Partnership between Patients, Nurses and Doctors in Neuroendocrine Tumors

(J07) Hörsch D et al. Long-Term Treatment with Telotristat Ethyl (TE) in Patients with Carcinoid Syndrome (CS) Symptoms: Results from TELEPATH Study

(J08) Khan M et al. Differential Diagnosis (DDx) of Carcinoid Syndrome Diarrhea (CSD): A Systematic Literature Review (SLR)

*The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.*
(J09) La Salvia A et al. Ocular Metastases in Neuroendocrine Tumors Patients: Clinical Experience and Management

(J10) Laing E et al. Exploring Nutrition Screening and Management Practices among Health Professionals Managing Patients with Neuroendocrine Tumours

(J11) Lamarca A et al. Management of Bone Metastases (BMs) in Patients (pts) with Neuroendocrine Neoplasms (NENs): Findings from a Retrospective Study


(J13) Pevny S et al. Systemic Anti-Cancer Therapies Impair the Nutritional Status of Neuroendocrine Tumor Patients

(J14) Spada F et al. An Italian Multicenter Study in Patients with Advanced Mixed Adeno-Neuroendocrine Carcinomas (MANECs) of the Gastro-Entero-Pancreatic Tract Treated with Chemotherapy


(J16) Xue B et al. Clinical Value of Endoscopic Ultrasonography in Treatment of Rectal Neuroendocrine Neoplasms with Endoscopic Submucosal Dissection

(J17) Xue B et al. Endoscopic Treatment of 46 Cases of Gastrointestinal Neuroendocrine Neoplasms

(J18) Yeung HM et al. Characterizing Immunophenotyping Changes with Pembrolizumab (P) Therapy in Grade 3 Neuroendocrine Neoplasms (G3 NENs)

K. NUCLEAR MEDICINE - IMAGING AND THERAPY (PRRT)

(K01) Aalbersberg E et al. Radiomics: A State-of-the-Art Tool for 68Ga-DOTATATE PET Imaging in NET

(K02) Antwi K et al. 68Ga-Exendin-4 PET/CT Specifically Detects Insulinomas in MEN-1 Patients

(K03) Armeni E et al. Peptide Receptor Radionuclide Therapy (177Lutetium DOTATATE) as a Treatment Modality for Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)

(K04) Bello P et al. Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry

(K05) Bhatt A et al. Pancreatic Uptake in Ga-68 DOTATATE PET in a Series of Small Bowel Neuroendocrine Neoplasms: Metastasis, New Primary or Just Physiological Uptake?

(K06) Calabrò D et al. 68Ga-DOTANOC Positive Neuroendocrine Skeletal Lesions: Does the Primary Tumour Show a Preferential CT Pattern?

(K07) Chan D et al. Impact of [68Ga]-DOTATATE (DOTA) PET after Resection of Appendiceal NEN: A Retrospective Study

(K08) Chan D et al. Quantitative Analysis of FDG PET in Neuroendocrine Neoplasms (NEN): Metabolic Tumour Volume Is a Predictor of Poor Prognosis

(K09) Chan D et al. The Role of FDG and DOTATATE PET in Predicting PRRT Efficacy: A Quantitative Lesion-Based Analysis

(K10) Chirindel A et al. Subacute and Long Term Hepatotoxicity Risk after 90Y- OR 177LU-DOTATOC Therapy – Is Hepatic Tumour Burden on 68Ga-DOTATOC PET/CT Predictive of Liver Dysfunction?

(K11) Cox N et al. Ga-68 DOTATATE PET/CT: Is It Appropriate to Be Used as a Screening Imaging Modality in Patients with Raised Biochemical Markers and Non-Specific Symptoms?

(K12) De Dosso S et al. Detection Rate of Unknown Primary Tumours by Using Somatostatin Receptor PET/CT in Patients with Metastatic Neuroendocrine Tumours: A Meta-Analysis

(K13) De Mestier L et al. Correlation between Ki-67 and Uptake at 18FDG-PET in Pancreatic Neuroendocrine Tumors: A Lesion-by-Lesion Analysis

(K14) De Mestier L et al. Prognostic Impact of Uptake at 18Fluoro-dihydroxy-phenylalanine (FDOPA-PET) in Advanced Small-Intestine Neuroendocrine Tumors (siNET)

(K15) Dioca MH et al. Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) 90Y-Dotatoc in Neuroendocrine Tumors (NETs) Patients: Single-Institution Retrospective Analysis

(K16) Fatima A et al. Analysing the Effectiveness Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. A Journey Towards Optimising the Treatment Options for NET

(K17) Fröss-Baron K et al. Is 177Lu-DOTA-Octreotide Therapy Effective and Safe in Patients with Advanced Pancreatic Neuroendocrine Tumours Who Have Previously Undergone Chemotherapy?
**Abstract Titles**

OA (K18) Goncalves I et al. Characteristics and Outcomes of Therapy-Related Myeloid Neoplasms after Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Neoplasm (NEN): A Single Centre Series

(K19) Hung TJ et al. Clinical Efficacy in Treatment of Metastatic Gastrinoma and Glucagonoma with Peptide Receptor Radionuclide Therapy (PRRT) - A Single Centre Experience

(K20) Karfis I et al. Combined Ga-DOTATATE and FDG PET Imaging Improves Prognostic Stratification In Metastatic Gastroenteropancreatic Neuroendocrine Neoplasias (GEP-NENs)

(K21) Konsek S et al. Usefulness of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)

(K22) Kunikowska J et al. Polish Multicenter Experience with Tandem Peptide Receptor Radionuclide Therapy Using 90Y/177Lu-DOTATATE in Neuroendocrine Tumors

(K23) Laskaratos F et al. Assessment of Changes in Mesenteric Fibrosis (MF) after Peptide Receptor Radionuclide Therapy (PRRT) in Midgut Neuroendocrine Tumours (NETs)

(K24) Liberini V et al. Can Texture Analysis Be Used for a Vivo “Imaging Biopsy” in Neuroendocrine Tumors? A First Step Feasibility Study with 68Ga-DOTATOC PET/CT

(K25) Mapelli P et al. Dual Tracer 68Ga-DOTATOC and 18F-FDG PET/CT for Preoperative Risk Assessment of Pancreatic Neuroendocrine Neoplasms (PanNENs)

(K26) Mapelli P et al. Texture Analysis of Dual Tracer 68Ga-DOTATOC and 18F-FDG PET/CT for Preoperative Risk Evaluation in Pancreatic Neuroendocrine Neoplasms (PanNENs): An Explorative Investigation

(K27) Marin G et al. Impaired Kidney Function Is Associated with Higher Absorbed Dose to Organs-at-Risk in 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT)

(K28) Marques B et al. 177Lu-DOTA-TATE Therapy in Midgut Neuroendocrine Tumours: Experience of a Tertiary Center

(K29) Mitjavila M et al. Patients with Advanced Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Data from Spanish SEPTRALU Registry

(K30) Nicolas G et al. OPS-C-001: A Phase II/II Study to Investigate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor (SSTR)-Positive Neuroendocrine Tumours (NETs)

(K31) Pilati E et al. Impact of 68Ga DOTATOC PET/CT in the Therapeutic Management of Neuroendocrine Tumors

(K32) Prinzi N et al. Somatostatin Analogues (SSAs) in Association to Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Well-Differentiated (WD) Entero-Pancreatic Neuroendocrine Tumours (EP-NETs): A Monocentric Retrospective Study

(K33) Puranik A et al. Does Dual FDG and Ga-68 DOTANOC PET/CT Impact Survival in Patients with WHO Grade 2 GEP-NETs?

(K34) Puranik A et al. Peptide Receptor Radionuclide Therapy Using 177Lu and 90Y-DOTATATE in Metastatic Treatment-Refractory Medullary Thyroid Cancer

(K35) Rottenburger C et al. Evaluation of the CCK-2 Receptor Agonist 177Lu-PP-F11N for PRRT of Medullary Thyroid Carcinoma - Results of a Phase 0 „Lumed” Study

(K36) Saavedra C et al. Current Experience in Heavily Pretreated Metastatic Neuroendocrine Tumors (NET) Treated with 177Lu-DOTATATE (LU). A Single Institution Experience

(K37) Strosberg J et al. LUTATHERA® Treatment Benefits Patients Even with Moderately Impaired Baseline Renal Function

(K38) Sullivan L et al. The Efficacy of Lutetium-177 DOTATATE in Refractory Symptoms of Functional Pancreatic Neuroendocrine Tumours

OA (K39) Sundin A et al. 11C-Hydroxy-Ephedrine-PET/CT for Diagnosis of Pheochromocytomas and Parangangiomas and for Characterization of Equivocal Adrenal Incidentalomas

(K40) Sundlöv A et al. Long-Term Follow-Up of Pituitary Function after Individualized PRRT with 177Lu-DOTATATE

(K41) Zandee W et al. Peptide Receptor Radionuclide Therapy with Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

L. SURGICAL TREATMENT AND ABLATIVE THERAPIES

(L01) Andreasi V et al. Long-Term Oncological Outcomes after Distal Pancreatectomy for Neuroendocrine Neoplasms: A Comparison between Minimally Invasive and Open Approach Using Propensity Score
Abstract Titles

(L02) Bassi N et al. Outcomes of Surgery for Retroperitoneal and Proximal Vascular NET Associated Desmoplasia
(L03) Bongini M et al. Y-90 Radioembolization of Liver Metastases from Neuroendocrine (NET) Tumors
(L04) Chorna N et al. Pancreatic Neuroendocrine Tumors
(L05) Fatima A et al. Finding the Options of Managing Duodenal Carcinoids in Pakistan. A Retrospective Study in a Territory Care Setup
(L06) Heidsma C et al. Long-Term Quality of Life after Surgery for Pancreatic Neuroendocrine Tumors
(L07) Kaçmaz E et al. Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis
(L08) Kong G et al. Valvular Replacement in Patients with Carcinoid Heart Disease (CaHD) – Preliminary Surgical Experience
(L09) Lænkholm IT et al. Gastroenteropancreatic (GEP) Mixed Neuroendocrine-Non-Endocrine Neoplasms (MiNEN)
(L10) Maggino L et al. Cystic Pancreatic Neuroendocrine Neoplasms: A Multicenter International Cohort Study
(L11) Mao R et al. Lymph Node Dissection Does Not Improve Survival in Patients with Pancreatic Neuroendocrine Tumors: A Study of the National Cancer Database
(L12) Masui T et al. Ki-67 Index as a Guide to Surgical Management of Small Pancreatic Neuroendocrine Neoplasms for Lymph Node Metastasis
(L13) Milanetto AC et al. Ampullary Neuroendocrine Neoplasms: Surgical Experience in Italy
(L14) Milanetto AC et al. Changing Syndrome: A Focus on Pancreatico-Duodenal NeuroEndocrine Neoplasms
(L15) Milanetto AC et al. Duodenal NeuroEndocrine Neoplasms: Retrospective Analysis of 33 Cases Diagnosed in a Single Centre
(L16) Milanetto AC et al. Gonadal Metastases In Small Intestinal NeuroEndocrine Neoplasms
(L17) Milanetto AC et al. Non-Insulinoma Organic Hyperinsulinism in Adults: A Challenging Diagnosis and Therapeutic Management
(L18) Milanetto AC et al. Small Intestinal NeuroEndocrine Neoplasms in MEN-1 Syndrome: Could It Be MEN-4 Syndrome?
(L19) Miotto M et al. Peptide Receptor Radionuclide Therapy (PRRT) a Novel Option as Neoadjuvant Therapy for Pancreatic Neuroendocrine Tumors: A Surgical Series
(L20) Monteleone M et al. Recurrence after Liver Transplantation for Metastatic GEP-NET
(L21) Nappo G et al. The Number of Metastatic Lymphodes Is a Useful Predictive Factor for Recurrence after Surgery for Non-Metastatic Nonfunctional Neuroendocrine Tumor of the Pancreas
(L22) Nunez JE et al. Prognostic Factors Associated with the Efficacy of Hepatic Artery Embolization in Patients with Neuroendocrine Tumors
(L23) Oleinikov K et al. Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) as a Novel Therapeutic Approach in Highly-Selected Pancreatic Neuroendocrine Neoplasms (pNENs) Patients: Preliminary Report
(L24) Ricci C et al. A Cure Model Survival Analysis of Patients Affected by Pancreatic Neuroendocrine Neoplasms: The Bologna ENETS Center Experience
(L26) Ricci C et al. Histopathological Diagnosis of Appendiceal Neuroendocrine Neoplasm: When to Perform Right Hemicolecotomy? A Systematic Review and Meta-Analysis
(L27) Santucci N et al. Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1. An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d’étude des Tumeurs Endocrines) Cohort Study
(L28) Van Beek DJ et al. The Role of Tumor Functionality on Survival in MEN1-Related Pancreatic Neuroendocrine Tumors: Non-Functioning Pancreatic Neuroendocrine Tumors Versus Insulinomas
(L29) Weaver H et al. Glenfield Pulmonary Neuroendocrine Tumour Guidelines

M. NON DIGESTIVE NETS (BRONCHIAL, THYMIC, OTHERS) - DIAGNOSIS AND THERAPY

(M01) Athar A et al. Neuroendocrine Carcinoma of the Breast – A Rare Clinical Entity
(M02) Bengueddach A et al. Neuroendocrine Prostate Cancer: Molecular Features, Therapeutic Management and Future Directions; Two Cases Report
(M03) **Ferolla P et al.** Population Data from Atlant, Phase 2 Study Combination Trial between Long Acting Somatostatin Analogue (SSA) Lanreotide (LAN) and Temozolomide (TMZ) in Progressive Thoracic (Lung/Thymus) Well Differentiated NET (Carcinoid) (TNETS)

(M04) **Hernando J et al.** Long-Term Follow-Up (FU) in Patients (pts) with Primary Lung Carcinoid Tumors (LCT): Is It really Cost-Effective?

(M05) **Patané A et al.** Predictive Value of Percentage of Ki-67 Expression in Bronchopulmonary Carcinoid Tumors

(M06) **Łowczak A et al.** Evaluation of OS and PFS in Patients with Pulmonary Neoplasms Including LCNEC and NECG3

---

N. ENDOCRINE MALIGNANCIES (MTC, PHEOCHROMOCYTOMA) - DIAGNOSIS AND THERAPY

(N01) **Armeni E et al.** Insight into the Management of Chromaffin Cell Derived Tumours - Experience from Two ENETS Centres of Excellence

(N02) **Bengueddach A et al.** A Rare Case of Pheochromocytoma with Carcinoid Syndrome: A Case Report and Literature Review

(N03) **Hayes AR et al.** Metastatic Medullary Thyroid Cancer (MTC): Is There a Role for Peptide Receptor Radionuclide Therapy (PRRT)?

---

O. CASE REPORTS

(O01) **Abu-Hijlih R et al.** Primary Neuroendocrine Carcinoma of the Thymus

(O02) **Aguirre-Allende I et al.** Surgery for Non-Functioning Pancreatic Neuroendocrine Tumour with Liver Metastases: A Case Report and Literature Review

(O03) **Barquin A et al.** Prolonged Response to 177Lu-DOTATATE in a Patient with a Heavily Pre-treated Rectal NET

(O04) **Bernardo YM et al.** Controlling Severe Hypoglycemia with Everolimus plus 177Lu-DOTATATE in Metastatic Insulinoma: Two Cases

(O05) **Chen X et al.** Gallbladder Mixed Adenoneuroendocrine Carcinoma: A Case Report

(O06) **Fatima A et al.** Appendiceal Neuroendocrine Tumor Causing Primary Infertility - A Case Report

(O07) **Femia D et al.** Unexpected Expression of Estrogen and Progesterone Receptor (ER and PgR) and Response to Aromatase Inhibitors (AI) in Neuroendocrine Tumor (NET) of the Lung

(O08) **Galesanu C et al.** Neuroendocrine Tumors of the Lung (Lu-NETs) - Case Report

(O09) **González Devia D et al.** Recurrent Hypoglycemia Related by Sporadic Malignant Insulinomatosis: Case Report

(O10) **Grimaldi F et al.** Continuous Glucose Monitoring in the Screening of Insulinomas

(O11) **Hasanbegović M et al.** Sporadic Gastrinoma of Major Duodenal Papilla in Young Female Patient: When Proton Pump Inhibitor Withdrawal Opens a Search for Mystical Primary Lesion

(O12) **Haydar Ali Tajuddin A et al.** Staged Inferior Vena Cava (IVC) Sampling for ACTH in a Von-Hippel-Lindau Syndrome (VHL) Patient with Cushing’s Syndrome, Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma

(O13) **Iorio J et al.** 68Ga-DOTA-TATE PET/CT Role in a Case Report of Transformation of Adenocarcinoma to Well-Differentiated Neuroendocrine Tumor

(O14) **Karfs I et al.** Successful and Durable Glycemic-Disease Control after PRRT in a Patient with Malignant Insulinoma

(O15) **Kehili H et al.** Neuroendocrine Tumor of the Gallbladder: 2 Cases Report

(O16) **Kovacheva-Slavova M et al.** Multimodal Management of Neuroendocrine Lung Tumor with Liver Metastases – A Case Report

(O17) **Lawal S et al.** An Interesting Case of Multiple Pancreatic Neuroendocrine Tumour: Normoglycaemic Glucagonoma with Concurrent Diagnosis of Gastrinoma

(O18) **Lengyel I et al.** Severe Cushing’s Disease Caused by Lung Neuroendocrine Tumor

(O19) **Lengyel I et al.** Two Neuroendocrine Tumors in One Patient – A Case of Multiple Endocrine Neoplasia Type1

(O20) **Markovich A et al.** Pregnancy with the Use of Long-Acting SSA Administration: A Case Report

(O21) **Mastrangelo L et al.** Combined Associating Right Trisectionectomy and Spleen Distal Pancreatectomy for a Rare Case of Ectopic Adrenocorticotrophic Hormone Syndrome Caused by a Metastatic Neuroendocrine Tumor of the Pancreas

*The numbers of the abstracts e.g. A01, B01, etc. are the same as of the posters displayed in the exhibition hall.*
<table>
<thead>
<tr>
<th>Abstract Titles</th>
</tr>
</thead>
<tbody>
<tr>
<td>(O22) Mollazadeh K et al. Treatment Effect in Secondary High Grade Pancreatic Neuroendocrine Tumour (Pan-NEt) - A Case Report</td>
</tr>
<tr>
<td>(O23) Moreira AP et al. In Vivo Portrait of von Hippel-Lindau Syndrome with 68Ga-DOTANOC PET-CT</td>
</tr>
<tr>
<td>(O25) Patané A et al. Diffuse Idiopathic Pulmonary Neuroendocrine Cells Hyperplasia (DIPNECH)/Tumorlets</td>
</tr>
<tr>
<td>(O26) Peralta Ferreira M et al. Neuroendocrine Tumor of Unknown Primary Site?</td>
</tr>
<tr>
<td>(O27) Reher D et al. Pancreatitis Due to Pancreatic Metastases of Small Bowel and Lung Neuroendocrine Tumors</td>
</tr>
<tr>
<td>(O28) Sakata K et al. Thyrotropin and Thyrotropin-Releasing Hormone Co-Producing Pituitary Gangliocytoma: Case Report and Review of Literature</td>
</tr>
<tr>
<td>(O29) Soczomski P et al. A Case Report of a Family with MEN 1 Syndrome and Renal Cancer – Should We Change Our Thinking about Typical MEN 1 Tumors?</td>
</tr>
<tr>
<td>(O30) Sripodok S et al. A Case Report of Gallbladder Neuroendocrine Tumor</td>
</tr>
<tr>
<td>(O31) Valerieve Y et al. Pancreatic Insulinoma – A Case of Three Small Tumors</td>
</tr>
<tr>
<td>(O32) Wang X et al. S-1 and Temozolomide May Be an Effective Second-Line Treatment for Neuroendocrine Carcinoma of the Breast</td>
</tr>
<tr>
<td>(O33) Xue B et al. Neuroendocrine Tumor at Rectum with Liver Metastasis: A Case Report</td>
</tr>
<tr>
<td>(O34) Yadlapalli CD et al. A Rare Case of Metastatic High Grade (G3), Poorly Differentiated Insulinoma</td>
</tr>
<tr>
<td>(O35) Yang Z et al. ACTH-Secreting Pancreatic Neoplasm Associated with Cushing Syndrome: Case Report</td>
</tr>
<tr>
<td>(O36) Yang Z et al. Intraoperative Insulin Assay Combined with Occlusion of the Pancreas for Localization of an Occult Insulinoma - A Case Report</td>
</tr>
</tbody>
</table>

**P. TRIALS IN PROGRESS/TRIALS IN CONCEPT**

| (P01) Bongiovanni A et al. A Randomized Phase II Trial of CAPTEM or FOLFIRI as Second-Line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of the Predictive Role of PET Imaging and Biological Markers (SENeca Study) |
| (P02) Hernando J et al. Phase II Multicohort Study of Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NEs) of Lung and Gastroenteropancreatic (GEP) Origin (DUNE Trial, GETNE 1601) |
| (P03) Isyangulova A et al. The Analysis of Mutations at Patients with Neuroendocrine Tumors (P04 Kos-Kudla B et al. Lanreotide Autogel 120mg (LAN) in Patients (pts) with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NEts): Prospective Observational NETways Study |
| (P05) Lamarc A et al. TELEFIRST | First-line Lanreotide(LAN) + Telotristat ethyl(TE) / Placebo(PBO in Patients(pts) with Advanced Well-Differentiated Small Intestinal Neuroendocrine Tumours(siNET with Highly-Functioning Carcinoid Syndrome(CS): Randomized Phase III Trial |
| (P06) Singh S et al. LUTATHERA® in First Line Therapy of G2 and G3 GEP-NET |
| (P07) Singh S et al. LUTATHERA® in Lung and Rare NET |
| (P08) Virgolini I et al. Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NEts |
| (P09) Zaheer S et al. Ga-68 DOTATEPEPTIDE PET/CT and 131I-MIBG Scans to Determine Feasibility of PRRT in Neuroblastoma |